Cellectar Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2004
Net Income	-37.98	-28.6	-24.12	-15.09	-14.09	-15.48	-15.01	-9.36	-5.5	-8.05	Upgrade
Depreciation & Amortization	0.25	0.24	0.23	0.21	0.19	0.08	1.55	0.36	0.36	0.37	Upgrade
Share-Based Compensation	2.41	1.45	1.12	0.47	0.87	0.72	0.76	0.53	0.45	0.85	Upgrade
Other Operating Activities	2.95	1.69	0.2	0.49	1.34	0.99	0.24	-2.99	-3.53	-2.01	Upgrade
Operating Cash Flow	-32.38	-25.22	-22.57	-13.93	-11.69	-11.44	-11.02	-8.28	-8.21	-8.84	Upgrade
Capital Expenditures	-0.86	-0.23	-0.14	-0.06	-0.02	-0.33	-0.35	-0.07	-0.06	-0.03	Upgrade
Investing Cash Flow	-0.86	-0.23	-0.14	-0.06	-0.02	-0.33	-0.35	-0.07	-0.06	-0.03	Upgrade
Share Issuance / Repurchase	0.79	0	1.25	60.36	9.02	9.08	4.91	12.36	3.3	12.39	Upgrade
Debt Issued / Paid	0	0	0	0.18	-0	-0	-0.09	-0.25	-0.12	4	Upgrade
Other Financing Activities	22.15	9.61	-	-	-	5.95	5.11	3.82	-0.47	-0.52	Upgrade
Financing Cash Flow	22.94	9.61	1.25	60.55	9.02	15.02	9.93	15.94	2.71	15.87	Upgrade
Net Cash Flow	-10.3	-15.84	-21.46	46.55	-2.7	3.25	-1.44	7.59	-5.56	7	Upgrade
Free Cash Flow	-33.24	-25.45	-22.71	-14	-11.72	-11.77	-11.37	-8.35	-8.27	-8.87	Upgrade
Free Cash Flow Per Share	-2.72	-3.61	-4.09	-7.06	-15.27	-39.74	-81.01	-191.33	-1057.76	-1931.35	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).